Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 1 |
Bispecific antibody | 1 |
Top 5 Target | Count |
---|---|
NLRP3(NACHT, LRR and PYD domains-containing protein 3) | 1 |
AVPR1A x AVPR1B | 1 |
Target |
Mechanism AVPR1A agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NLRP3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GLP-1R agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 May 2025 |
Sponsor / Collaborator [+1] |
Start Date01 May 2025 |
Sponsor / Collaborator [+2] |
Start Date14 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
InflaMab ( NLRP3 ) | Glaucoma More | Preclinical |
Ac3IV ( AVPR1A x AVPR1B ) | Diabetes Mellitus More | Preclinical |
(Val8)GLP-1(Ulster University) ( GLP-1R ) | Diabetes Mellitus, Type 2 More | Pending |